Tracheotomie bei Angioödem unter ACE-Hemmer-Therapie?

Schröder, T.; Sachse, F.; Rudack, Claudia

doi:10.1007/s00106-004-1107-z

Cited by 2 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Анализ результатов инструментальных методов обследования пациентов, в частности суточного мониторирования АД, показал статистически значимые различия показателей среднего систолического, дневного систолического и дневного диастолического АД у пациентов бронхоспазма и не купируется противокашлевыми препаратами центрального действия [15]. Кроме того, кашель способен вызвать рвоту, охриплость голоса, недержание мочи в момент приступа, пневмоторакс, переломы ребер и грыжи [15][16][17]. Возникновение данной НР ухудшает качество повседневной жизни пациентов с кардиоваскулярной патологией.…”

Section: результатыunclassified

Clinical Signs and Medical History as Predictors of Enalapril-Associated Dry Cough in Cardiovascular Patients

Сычев

Denisenko²,

Качанова³

et al. 2023

Bezopasnost' i risk farmakoterapii

View full text Add to dashboard Cite

Angiotensin-converting enzyme inhibitors (ACEIs) are among the most prescribed and effective medicinal products for the treatment of several cardiovascular diseases. According to a number of studies, 30% of patients taking ACEIs develop adverse drug reactions (ADRs), and treatment discontinuation is often required as a result. The most common ADR associated with ACEIs is a dry (non-productive) cough. Nevertheless, the clinical signs and medical history predictive of this ADR in cardiovascular patients are still understudied.The aim of the study was to analyse the clinical signs and medical history predictive of cough in patients with cardiovascular conditions treated with enalapril.Materials and methods. The study was carried out in 2019–2022 and enrolled 224 patients with essential hypertension (grades 2 and 3) treated with enalapril at a dose of 10–20 mg/day. The patients were assigned to 2 groups: Group 1 included 113 patients with enalapril-associated cough, while Group 2 (control group) comprised 104 patients without this ADR. At screening, all the patients underwent a general examination and a check of their allergy and medication history. Using the data obtained, the authors analysed the association of the clinical signs and medical history with the ADR of interest (dry cough).Results. In contrast to the control group, the group with ACEI-associated dry cough included more patients with a history of drug-induced toxicoderma (OR=5.639, CI 2.234–14.236, χ2=15.845, and p<0.001) or type 2 diabetes mellitus (OR=3.409, CI 1.461–7.953, χ2=8.7472, and p<0.01), a family history of bronchial asthma (OR=4.141, CI 2.066–8.299, χ2=17.417, and p<0.001), and a close family history of severe allergic reactions (OR=3.714, CI 1.720– 8.018, χ2=12.137, and p<0.001).Conclusions. A family history of allergy increases the probability of dry cough in patients taking ACEIs. In order to improve the safety of ACEI therapy, patients with cardiovascular conditions should be asked more detailed questions about their personal or first-degree family history of allergy.

show abstract

Section: результатыunclassified

Clinical Signs and Medical History as Predictors of Enalapril-Associated Dry Cough in Cardiovascular Patients

Сычев

Denisenko²,

Качанова³

et al. 2023

Bezopasnost' i risk farmakoterapii

View full text Add to dashboard Cite

show abstract

Angioneurotische Ödeme des Kopf-Hals-Bereiches unter der Therapie mit ACE-Hemmern

Wahbe

Schultz-Coulon

2007

HNO

View full text Add to dashboard Cite

During the observation period. 121 patients were treated for acute angioneurotic edema of the head and neck region. In 34 patients (=28.1%), edema was related to permanent treatment with ACE inhibitors. The overall frequency of angioedema and the percentage of ACE inhibitor related angioedema showed a continuous increase during the study period. There was a latency from the beginning of ACE inhibitor treatment until the first manifestation of angioedema of up to 13 years. In comparison with the group of edema patients without ACE inhibitor treatment, we found a threefold risk of recurrent edema in the ACE group. Women were affected by recurrent episodes more often than men. Until now, any individual assessment of the probable risk of developing an angioneurotic edema during ACE inhibitor treatment appears to be impossible.

show abstract

Tracheotomie bei Angioödem unter ACE-Hemmer-Therapie?

Cited by 2 publications

References 10 publications

Clinical Signs and Medical History as Predictors of Enalapril-Associated Dry Cough in Cardiovascular Patients

Clinical Signs and Medical History as Predictors of Enalapril-Associated Dry Cough in Cardiovascular Patients

Angioneurotische Ödeme des Kopf-Hals-Bereiches unter der Therapie mit ACE-Hemmern

Contact Info

Product

Resources

About